JP2016504284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504284A5 JP2016504284A5 JP2015542870A JP2015542870A JP2016504284A5 JP 2016504284 A5 JP2016504284 A5 JP 2016504284A5 JP 2015542870 A JP2015542870 A JP 2015542870A JP 2015542870 A JP2015542870 A JP 2015542870A JP 2016504284 A5 JP2016504284 A5 JP 2016504284A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- alkynyl
- independently
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 99
- 229910052799 carbon Inorganic materials 0.000 claims 95
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 55
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 49
- 150000004820 halides Chemical class 0.000 claims 47
- -1 aminothionyl Chemical group 0.000 claims 44
- 125000003118 aryl group Chemical group 0.000 claims 41
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000003710 aryl alkyl group Chemical group 0.000 claims 36
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000001540 azides Chemical class 0.000 claims 29
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 241000700605 Viruses Species 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000004001 thioalkyl group Chemical group 0.000 claims 12
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 11
- 125000004414 alkyl thio group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 241000712431 Influenza A virus Species 0.000 claims 3
- 241000713196 Influenza B virus Species 0.000 claims 3
- 241001115401 Marburgvirus Species 0.000 claims 3
- 241000710772 Yellow fever virus Species 0.000 claims 3
- 229940051021 yellow-fever virus Drugs 0.000 claims 3
- 241000725619 Dengue virus Species 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000712890 Junin mammarenavirus Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 241000713124 Rift Valley fever virus Species 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 241000712908 Tacaribe mammarenavirus Species 0.000 claims 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 2
- 241000710886 West Nile virus Species 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241000712892 Arenaviridae Species 0.000 claims 1
- 241001493160 California encephalitis virus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000710781 Flaviviridae Species 0.000 claims 1
- 241000190708 Guanarito mammarenavirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 206010023927 Lassa fever Diseases 0.000 claims 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 1
- 241000712898 Machupo mammarenavirus Species 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 241000712464 Orthomyxoviridae Species 0.000 claims 1
- 241000711504 Paramyxoviridae Species 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 241000713126 Punta Toro virus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000710951 Western equine encephalitis virus Species 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *C1=CN=C(*)NC1=* Chemical compound *C1=CN=C(*)NC1=* 0.000 description 155
- DNLJAPGUAPBXHE-RXDXJJGDSA-N CO[C@H]1[C@H](c2c[nH]c3c2ncnc3N)N[C@H](CO)[C@H]1O Chemical compound CO[C@H]1[C@H](c2c[nH]c3c2ncnc3N)N[C@H](CO)[C@H]1O DNLJAPGUAPBXHE-RXDXJJGDSA-N 0.000 description 2
- LLXZUZLCCNNAOM-JKUQZMGJSA-N C[C@@H](C1)N[C@H](CO)[C@H]1O Chemical compound C[C@@H](C1)N[C@H](CO)[C@H]1O LLXZUZLCCNNAOM-JKUQZMGJSA-N 0.000 description 2
- GUFBLOGHOCWZCD-POYBYMJQSA-N Nc1c2[nH]cc([C@@H]3N[C@H](CO)CC3)c2ncn1 Chemical compound Nc1c2[nH]cc([C@@H]3N[C@H](CO)CC3)c2ncn1 GUFBLOGHOCWZCD-POYBYMJQSA-N 0.000 description 2
- RSYWBFOPJYGRMR-GEVIPFJHSA-N Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@@H]3F)c2ncn1 Chemical compound Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@@H]3F)c2ncn1 RSYWBFOPJYGRMR-GEVIPFJHSA-N 0.000 description 2
- OBIXMCRFEXZXER-ARDNSNSESA-N Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@H]3O)c2ncn1 Chemical compound Nc1c2[nH]cc([C@@H]3N[C@H](CO)C[C@H]3O)c2ncn1 OBIXMCRFEXZXER-ARDNSNSESA-N 0.000 description 2
- HTKJHJQGNWKVRD-HQMQMISQSA-N Nc1ncnc2c1NCC2[C@@H](C1(F)F)N[C@H](CO)[C@H]1O Chemical compound Nc1ncnc2c1NCC2[C@@H](C1(F)F)N[C@H](CO)[C@H]1O HTKJHJQGNWKVRD-HQMQMISQSA-N 0.000 description 2
- WSYRZIZYUWPOLP-RGOKHQFPSA-N C#CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O Chemical compound C#CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O WSYRZIZYUWPOLP-RGOKHQFPSA-N 0.000 description 1
- DWELXPFRAWEKLB-XAVMHZPKSA-N CC(C(N1)=O)=CC([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C1O Chemical compound CC(C(N1)=O)=CC([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C1O DWELXPFRAWEKLB-XAVMHZPKSA-N 0.000 description 1
- WAPKAXXJFRIDCE-XAVMHZPKSA-N CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O Chemical compound CC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O WAPKAXXJFRIDCE-XAVMHZPKSA-N 0.000 description 1
- FMIRQNOVTQGDEW-RGOKHQFPSA-N CCC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O Chemical compound CCC(C=C1[C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)=C(N)NC1=O FMIRQNOVTQGDEW-RGOKHQFPSA-N 0.000 description 1
- CHQVICWFDPEJOK-UCROKIRRSA-N NC(C([C@@H]([C@@H]1O)N[C@H](CO)[C@H]1O)=CN1)=NC1=O Chemical compound NC(C([C@@H]([C@@H]1O)N[C@H](CO)[C@H]1O)=CN1)=NC1=O CHQVICWFDPEJOK-UCROKIRRSA-N 0.000 description 1
- CPOLMWXQKHMDTG-JYFAAPFMSA-N NC(N1)=CC=C([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O Chemical compound NC(N1)=CC=C([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O CPOLMWXQKHMDTG-JYFAAPFMSA-N 0.000 description 1
- VXCZUOGLGVWRIR-ZUMNNYEFSA-N NC(N1)=NC=C(C([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O Chemical compound NC(N1)=NC=C(C([C@@H]2O)N[C@H](CO)[C@H]2O)C1=O VXCZUOGLGVWRIR-ZUMNNYEFSA-N 0.000 description 1
- ABQFSPSUNQYJRN-HWBGAQDOSA-N NC(NC(C(C([C@@H]1O)N[C@H](CO)[C@H]1O)=C1)=O)=C1F Chemical compound NC(NC(C(C([C@@H]1O)N[C@H](CO)[C@H]1O)=C1)=O)=C1F ABQFSPSUNQYJRN-HWBGAQDOSA-N 0.000 description 1
- OVLGEFNKTPVUHW-NEPJDUFXSA-N Nc1ccc([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)cn1 Chemical compound Nc1ccc([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)cn1 OVLGEFNKTPVUHW-NEPJDUFXSA-N 0.000 description 1
- UMFCMUAQLLZTAO-MIRRECJXSA-N Nc1nc(O)c([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)c(O)n1 Chemical compound Nc1nc(O)c([C@@H]([C@@H]2O)N[C@H](CO)[C@H]2O)c(O)n1 UMFCMUAQLLZTAO-MIRRECJXSA-N 0.000 description 1
- CJCSSIACHRZLAQ-VVXQKDJTSA-N OC[C@H]([C@H](C1)O)NC1C1=CN=CNC1=O Chemical compound OC[C@H]([C@H](C1)O)NC1C1=CN=CNC1=O CJCSSIACHRZLAQ-VVXQKDJTSA-N 0.000 description 1
- FEYBDKGNVYMXKY-FXWAIPRXSA-N OC[C@H]([C@H]([C@H]1O)O)NC1C(C=CC(N1)=O)=C1O Chemical compound OC[C@H]([C@H]([C@H]1O)O)NC1C(C=CC(N1)=O)=C1O FEYBDKGNVYMXKY-FXWAIPRXSA-N 0.000 description 1
- XKRKHLSUXIRKHX-UCROKIRRSA-N OC[C@H]([C@H]([C@H]1O)O)N[C@H]1C(C(N1)=O)=COC1=O Chemical compound OC[C@H]([C@H]([C@H]1O)O)N[C@H]1C(C(N1)=O)=COC1=O XKRKHLSUXIRKHX-UCROKIRRSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727468P | 2012-11-16 | 2012-11-16 | |
| US61/727,468 | 2012-11-16 | ||
| PCT/US2013/070537 WO2014078778A2 (en) | 2012-11-16 | 2013-11-18 | Antiviral azasugar-containing nucleosides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504284A JP2016504284A (ja) | 2016-02-12 |
| JP2016504284A5 true JP2016504284A5 (enExample) | 2017-01-12 |
Family
ID=50731836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542870A Pending JP2016504284A (ja) | 2012-11-16 | 2013-11-18 | 抗ウイルス性アザ糖を含有するヌクレオシド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150291596A1 (enExample) |
| EP (2) | EP3251674A3 (enExample) |
| JP (1) | JP2016504284A (enExample) |
| AU (1) | AU2013344422A1 (enExample) |
| CA (1) | CA2890905A1 (enExample) |
| HK (1) | HK1212235A1 (enExample) |
| IL (1) | IL238785A0 (enExample) |
| MX (1) | MX2015005949A (enExample) |
| WO (1) | WO2014078778A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI483950B (zh) | 2009-09-21 | 2015-05-11 | Gilead Sciences Inc | 用於製備１’－取代碳核苷類似物之方法及中間物 |
| PH12013500035A1 (en) | 2010-07-22 | 2013-03-11 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| PL3097102T3 (pl) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego |
| SG10202109869XA (en) * | 2015-09-16 | 2021-10-28 | Gilead Sciences Inc | Methods for treating arenaviridae and coronaviridae virus infections |
| JP6948322B2 (ja) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン |
| AU2017241524B2 (en) | 2016-03-28 | 2021-07-08 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| CN106834546A (zh) * | 2017-03-20 | 2017-06-13 | 杭州迪安医学检验中心有限公司 | 一种基于熔解曲线法单管同时检测多种呼吸道病毒的引物及其应用 |
| ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| CN109053788A (zh) * | 2018-09-20 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种吡唑类化合物的制备方法 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| CN118662520A (zh) | 2020-01-27 | 2024-09-20 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
| EP4132651B1 (en) | 2020-04-06 | 2026-03-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| EP4172160A2 (en) | 2020-06-24 | 2023-05-03 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| CN111704619B (zh) * | 2020-07-30 | 2021-10-19 | 四川大学 | 一种Forodesine的制备方法 |
| HUE067491T2 (hu) | 2020-08-27 | 2024-10-28 | Gilead Sciences Inc | Vegyületek és eljárások vírusfertõzések kezelésére |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN114588159A (zh) * | 2020-12-07 | 2022-06-07 | 成都傲科新技术有限责任公司 | 一种治疗猫冠状病毒感染的化合物及其应用 |
| CA3223875A1 (en) * | 2021-06-25 | 2022-12-29 | Shigeru Matsuoka | Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections |
| IL310854A (en) | 2021-08-20 | 2024-04-01 | Shionogi & Co | Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity |
| CN113666941B (zh) * | 2021-09-01 | 2023-03-10 | 浙江珲达生物科技有限公司 | 一种2,3-O-异亚丙基-D-核糖酸-γ-内酯的重结晶方法 |
| US12552827B2 (en) * | 2022-01-21 | 2026-02-17 | Biocryst Pharmaceuticals, Inc. | Synthesis of an antiviral azasugar triphosphate |
| AU2023227794A1 (en) | 2022-03-02 | 2024-10-17 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP0630904A4 (en) * | 1992-08-26 | 1995-01-04 | Japan Tobacco Inc. | Novel nicotine derivative. |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| WO2003100009A2 (en) * | 2002-05-23 | 2003-12-04 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
| JP4464272B2 (ja) * | 2002-07-17 | 2010-05-19 | 独立行政法人科学技術振興機構 | 新規な非天然型塩基を有するヌクレオシド又はヌクレオチド及びその利用 |
| EP2189467A3 (en) | 2002-12-04 | 2010-09-08 | Mitsubishi Gas Chemical Company, Inc. | Method of fluorination by microwaves |
| US6780993B1 (en) * | 2003-02-19 | 2004-08-24 | Biocryst Pharmaceuticals, Inc. | Preparation of deazaguanine analog |
| MY139887A (en) | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| WO2006002231A1 (en) * | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| KR20070100237A (ko) * | 2004-10-29 | 2007-10-10 | 바이오크리스트 파마수티컬즈, 인코퍼레이티드 | 치료용 푸로피리미딘 및 티에노피리미딘 |
| AU2006247738A1 (en) * | 2005-05-13 | 2006-11-23 | Eli Lilly And Company | Substituted N-arylpyrrolidines as selective androgen receptor modulators |
| CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| TW200738649A (en) * | 2005-11-22 | 2007-10-16 | Smithkline Beecham Corp | Calcilytic compounds |
| KR101461680B1 (ko) | 2005-12-02 | 2014-11-19 | 바이엘 헬스케어 엘엘씨 | 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체 |
| WO2007109459A2 (en) | 2006-03-21 | 2007-09-27 | Janssen Pharmaceutica, Nv | Pyridines and pyridine n-oxides as modulators of thrombin |
| WO2007125061A1 (en) | 2006-04-27 | 2007-11-08 | Glaxo Group Limited | Spirocompounds useful as modulators for dopamine d3 receptors |
| SG177974A1 (en) * | 2007-01-12 | 2012-02-28 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| WO2008141079A1 (en) * | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
| EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| EP2348854A4 (en) * | 2008-09-22 | 2012-03-14 | Einstein Coll Med | METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING |
| WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
| WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
| EP2898885B1 (en) * | 2010-10-15 | 2017-11-22 | Biocryst Pharmaceuticals, Inc. | Pyrrolopyrimidine derivatives for use in the treatment of viral infections |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
-
2013
- 2013-11-18 AU AU2013344422A patent/AU2013344422A1/en not_active Abandoned
- 2013-11-18 EP EP17162146.9A patent/EP3251674A3/en not_active Withdrawn
- 2013-11-18 CA CA2890905A patent/CA2890905A1/en not_active Abandoned
- 2013-11-18 MX MX2015005949A patent/MX2015005949A/es unknown
- 2013-11-18 US US14/441,762 patent/US20150291596A1/en not_active Abandoned
- 2013-11-18 EP EP13855441.5A patent/EP2919785A4/en not_active Withdrawn
- 2013-11-18 HK HK16100301.6A patent/HK1212235A1/xx unknown
- 2013-11-18 JP JP2015542870A patent/JP2016504284A/ja active Pending
- 2013-11-18 WO PCT/US2013/070537 patent/WO2014078778A2/en not_active Ceased
-
2015
- 2015-05-13 IL IL238785A patent/IL238785A0/en unknown
-
2017
- 2017-03-31 US US15/475,507 patent/US20170267681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504284A5 (enExample) | ||
| JP2013544788A5 (enExample) | ||
| JP2015514772A5 (enExample) | ||
| HRP20150487T1 (hr) | Kompozicije za primjenu u lijeäśenju virusnih infekcija | |
| JP2025098020A5 (enExample) | ||
| WO2007103111A8 (en) | Antiviral drugs for treatment of arenavirus infection | |
| NZ596014A (en) | Dihydroorotate - dehydrogenase inhibitors as virostatic compounds | |
| JP2011516610A5 (enExample) | ||
| IL277160B1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2016518305A5 (enExample) | ||
| CY1115253T1 (el) | Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv | |
| RU2020116571A (ru) | N4-гидроксицитидин и производные и связанные с этим противовирусные применения | |
| JP2013537203A5 (enExample) | ||
| JP2015517555A5 (enExample) | ||
| JP2013512915A5 (enExample) | ||
| HRP20190987T1 (hr) | Kompozicije i postupci za modulaciju ekspresije hbv i ttr | |
| RU2014106765A (ru) | Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов | |
| ATE475660T1 (de) | Antivirale verbindungen | |
| WO2014106019A3 (en) | Novel antiviral agents against hbv infection | |
| JP2009535352A5 (enExample) | ||
| NZ597544A (en) | Modified 4'-nucleosides as antiviral agents | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| FI3981437T3 (fi) | Nukleiinihapporokotteita | |
| JP2013503880A5 (enExample) | ||
| JP2018135343A5 (enExample) |